Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596)

Market Cap	2.54B
Revenue (ttm)	27.00M
Net Income (ttm)	-1.33B
Shares Out	57.83M
EPS (ttm)	-23.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,100
Average Volume	1,648,435
Open	44.00
Previous Close	44.00
Day's Range	43.00 - 45.00
52-Week Range	38.00 - 94.00
Beta	0.62
RSI	45.37
Earnings Date	May 14, 2025

About TYO:4596

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 19
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4596

Financial Performance

In 2024, TYO:4596's revenue was 27.00 million, a decrease of -30.77% compared to the previous year's 39.00 million. Losses were -1.33 billion, -10.54% less than in 2023.